{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:49:36Z","timestamp":1788432576279,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Foundation (NRF) funded by the Korean government","award":["2019M3E5D1A01069361"],"award-info":[{"award-number":["2019M3E5D1A01069361"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the study was to investigate the prognostic significance of the advanced lung cancer inflammation index (ALI) in patients with limited-stage small-cell lung cancer (LS-SCLC) undergoing definite chemo-radiotherapy (CRT). We included 87 patients with LS-SCLC from South Korea, treated between 2005 and 2019 with definite CRT. ALI was calculated using body mass index, serum albumin, and neutrophil\u2013lymphocyte ratio. We categorized 38 patients into the high ALI group (ALI\u2009\u2265\u200944.3) and 48 into the low ALI group (ALI\u2009&lt;\u200944.3). Patients in the high ALI group exhibited longer overall survival (OS) than patients in the low ALI group. In multivariate analysis, prophylactic cranial irradiation (hazard ratio [HR]\u2009=\u20090.366, 95% confidence interval [CI] 0.20\u20130.66, P\u2009=\u20090.0008), and high ALI (HR\u2009=\u20090.475, 95% CI 0.27\u20130.84, P\u2009=\u20090.0103) were identified as independent prognostic factors for predicting better OS. Notably, a high ALI score was particularly indicative of longer survival in patients treated with the combination of etoposide and cisplatin. In conclusion, this study demonstrated that a high pretreatment ALI was significantly associated with better OS in patients with LS-SCLC undergoing definite CRT. This suggests that ALI could be a useful tool for predicting prognosis and guiding chemotherapy regimen selections in clinical practice for LS-SCLC.<\/jats:p>","DOI":"10.1038\/s41598-024-61145-9","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:02:12Z","timestamp":1714989732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Bo Mi","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boksoon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Guen","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Joo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Won","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"61145_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4143\/crt.2022.128","volume":"54","author":"MJ Kang","year":"2022","unstructured":"Kang, M. J. et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2019. Cancer Res. Treat. 54, 330\u2013344. https:\/\/doi.org\/10.4143\/crt.2022.128 (2022).","journal-title":"Cancer Res. Treat."},{"key":"61145_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Primers 7, 3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"61145_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/jco.21.01639","volume":"40","author":"JA Bogart","year":"2022","unstructured":"Bogart, J. A., Waqar, S. N. & Mix, M. D. Radiation and systemic therapy for limited-stage small-cell lung cancer. J. Clin. Oncol. 40, 661\u2013670. https:\/\/doi.org\/10.1200\/jco.21.01639 (2022).","journal-title":"J. Clin. Oncol."},{"key":"61145_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-319-40389-2_3","volume":"170","author":"GA Woodard","year":"2016","unstructured":"Woodard, G. A., Jones, K. D. & Jablons, D. M. Lung cancer staging and prognosis. Cancer Treat. Res. 170, 47\u201375. https:\/\/doi.org\/10.1007\/978-3-319-40389-2_3 (2016).","journal-title":"Cancer Treat. Res."},{"key":"61145_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","volume":"103","author":"F Nasim","year":"2019","unstructured":"Nasim, F., Sabath, B. F. & Eapen, G. A. Lung cancer. Med. Clin. North Am. 103, 463\u2013473. https:\/\/doi.org\/10.1016\/j.mcna.2018.12.006 (2019).","journal-title":"Med. Clin. North Am."},{"key":"61145_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444. https:\/\/doi.org\/10.1038\/nature07205 (2008).","journal-title":"Nature"},{"key":"61145_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/hed.27402","volume":"45","author":"DD Kao","year":"2023","unstructured":"Kao, D. D. et al. Neutrophil-to-lymphocyte ratio as a predictor of surgical outcomes in head and neck cancer. Head Neck 45, 1903\u20131912. https:\/\/doi.org\/10.1002\/hed.27402 (2023).","journal-title":"Head Neck"},{"key":"61145_CR8","first-page":"3017","volume":"14","author":"P Li","year":"2022","unstructured":"Li, P., Li, H., Ding, S. & Zhou, J. NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma. Am. J. Transl. Res. 14, 3017\u20133027 (2022).","journal-title":"Am. J. Transl. Res."},{"key":"61145_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-019-5903-y","volume":"19","author":"T Hirahara","year":"2019","unstructured":"Hirahara, T. et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer 19, 672. https:\/\/doi.org\/10.1186\/s12885-019-5903-y (2019).","journal-title":"BMC Cancer"},{"key":"61145_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12957-016-0889-2","volume":"14","author":"WK Xia","year":"2016","unstructured":"Xia, W. K. et al. Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J. Surg. Oncol. 14, 127. https:\/\/doi.org\/10.1186\/s12957-016-0889-2 (2016).","journal-title":"World J. Surg. Oncol."},{"key":"61145_CR11","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1038\/s41598-018-22425-3","volume":"8","author":"J Ma","year":"2018","unstructured":"Ma, J. et al. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci. Rep. 8, 4044. https:\/\/doi.org\/10.1038\/s41598-018-22425-3 (2018).","journal-title":"Sci. Rep."},{"key":"61145_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","volume":"13","author":"SH Jafri","year":"2013","unstructured":"Jafri, S. H., Shi, R. & Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC Cancer 13, 158. https:\/\/doi.org\/10.1186\/1471-2407-13-158 (2013).","journal-title":"BMC Cancer"},{"key":"61145_CR13","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/j.cllc.2015.03.005","volume":"16","author":"X He","year":"2015","unstructured":"He, X. et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin. Lung Cancer 16, e165-171. https:\/\/doi.org\/10.1016\/j.cllc.2015.03.005 (2015).","journal-title":"Clin. Lung Cancer"},{"key":"61145_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-022-09774-z","volume":"22","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Wang, D., Sun, T., Li, W. & Dang, C. Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection. BMC Cancer 22, 684. https:\/\/doi.org\/10.1186\/s12885-022-09774-z (2022).","journal-title":"BMC Cancer"},{"key":"61145_CR15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.2147\/cmar.S295952","volume":"13","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Advanced lung cancer inflammation index is a prognostic factor of patients with small-cell lung cancer following surgical resection. Cancer Manag. Res. 13, 2047\u20132055. https:\/\/doi.org\/10.2147\/cmar.S295952 (2021).","journal-title":"Cancer Manag. Res."},{"key":"61145_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies, J. et al. Cutoff Finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7, e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862 (2012).","journal-title":"PLoS ONE"},{"key":"61145_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-021-02761-1","volume":"19","author":"I Sumiyoshi","year":"2021","unstructured":"Sumiyoshi, I. et al. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: A retrospective observational study. J. Transl. Med. 19, 92. https:\/\/doi.org\/10.1186\/s12967-021-02761-1 (2021).","journal-title":"J. Transl. Med."},{"key":"61145_CR18","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/jcsm.13032","volume":"13","author":"M Song","year":"2022","unstructured":"Song, M. et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. J. Cachexia Sarcopenia Muscle 13, 2504\u20132514. https:\/\/doi.org\/10.1002\/jcsm.13032 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"61145_CR19","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/s1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15, e493-503. https:\/\/doi.org\/10.1016\/s1470-2045(14)70263-3 (2014).","journal-title":"Lancet Oncol."},{"key":"61145_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcp.10014","volume":"189","author":"P Shamamian","year":"2001","unstructured":"Shamamian, P. et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: A role for inflammatory cells in tumor invasion and angiogenesis. J. Cell Physiol 189, 197\u2013206. https:\/\/doi.org\/10.1002\/jcp.10014 (2001).","journal-title":"J. Cell Physiol"},{"key":"61145_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/s0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: Back to Virchow?. Lancet 357, 539\u2013545. https:\/\/doi.org\/10.1016\/s0140-6736(00)04046-0 (2001).","journal-title":"Lancet"},{"key":"61145_CR22","first-page":"63","volume":"49","author":"E Jab\u0142o\u0144ska","year":"2001","unstructured":"Jab\u0142o\u0144ska, E. et al. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch. Immunol. Ther. Exp. (Warsz) 49, 63\u201369 (2001).","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"61145_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/172460080401900208","volume":"19","author":"P Lissoni","year":"2004","unstructured":"Lissoni, P. et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int. J. Biol. Markers 19, 135\u2013140. https:\/\/doi.org\/10.1177\/172460080401900208 (2004).","journal-title":"Int. J. Biol. Markers"},{"key":"61145_CR24","first-page":"1875","volume":"6","author":"AK Eerola","year":"2000","unstructured":"Eerola, A. K., Soini, Y. & P\u00e4\u00e4kk\u00f6, P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6, 1875\u20131881 (2000).","journal-title":"Clin. Cancer Res."},{"key":"61145_CR25","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/1078-0432.Ccr-19-2034","volume":"26","author":"A Arina","year":"2020","unstructured":"Arina, A., Gutiontov, S. I. & Weichselbaum, R. R. Radiotherapy and immunotherapy for cancer: From \u201csystemic\u201d to \u201cmultisite\u201d. Clin. Cancer Res. 26, 2777\u20132782. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2034 (2020).","journal-title":"Clin. Cancer Res."},{"key":"61145_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5045\/br.2016.51.3.157","volume":"51","author":"H Jeong","year":"2016","unstructured":"Jeong, H., Bok, S., Hong, B. J., Choi, H. S. & Ahn, G. O. Radiation-induced immune responses: Mechanisms and therapeutic perspectives. Blood Res. 51, 157\u2013163. https:\/\/doi.org\/10.5045\/br.2016.51.3.157 (2016).","journal-title":"Blood Res."},{"key":"61145_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12094-022-02936-2","volume":"25","author":"D Chen","year":"2023","unstructured":"Chen, D. et al. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy. Clin. Transl. Oncol. 25, 226\u2013235. https:\/\/doi.org\/10.1007\/s12094-022-02936-2 (2023).","journal-title":"Clin. Transl. Oncol."},{"key":"61145_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7150\/jca.21703","volume":"9","author":"H Luo","year":"2018","unstructured":"Luo, H. et al. Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy\u2014a single center experience. J. Cancer 9, 182\u2013188. https:\/\/doi.org\/10.7150\/jca.21703 (2018).","journal-title":"J. Cancer"},{"key":"61145_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3857\/roj.2019.00220","volume":"37","author":"EY Park","year":"2019","unstructured":"Park, E. Y. et al. Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat. Oncol. J. 37, 166\u2013175. https:\/\/doi.org\/10.3857\/roj.2019.00220 (2019).","journal-title":"Radiat. Oncol. J."},{"key":"61145_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12967-017-1326-1","volume":"15","author":"YS Tong","year":"2017","unstructured":"Tong, Y. S., Tan, J., Zhou, X. L., Song, Y. Q. & Song, Y. J. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J. Transl. Med. 15, 221. https:\/\/doi.org\/10.1186\/s12967-017-1326-1 (2017).","journal-title":"J. Transl. Med."},{"key":"61145_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1634\/theoncologist.2016-0443","volume":"22","author":"KA Scilla","year":"2017","unstructured":"Scilla, K. A. et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 22, 737\u2013742. https:\/\/doi.org\/10.1634\/theoncologist.2016-0443 (2017).","journal-title":"Oncologist"},{"key":"61145_CR32","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/jco.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi, A. et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J. Clin. Oncol. 30, 1692\u20131698. https:\/\/doi.org\/10.1200\/jco.2011.40.4905 (2012).","journal-title":"J. Clin. Oncol."},{"key":"61145_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/oxfordjournals.annonc.a058931","volume":"5","author":"DV Skarlos","year":"1994","unstructured":"Skarlos, D. V. et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann. Oncol. 5, 601\u2013607. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058931 (1994).","journal-title":"Ann. Oncol."},{"key":"61145_CR34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3892\/ol.2019.10459","volume":"18","author":"Z Pan","year":"2019","unstructured":"Pan, Z. et al. Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection. Oncol. Lett. 18, 1513\u20131520. https:\/\/doi.org\/10.3892\/ol.2019.10459 (2019).","journal-title":"Oncol. Lett."},{"key":"61145_CR35","doi-asserted-by":"publisher","first-page":"10341","DOI":"10.2147\/cmar.S263863","volume":"12","author":"F Liu","year":"2020","unstructured":"Liu, F., Zhou, S., Tan, L., Jiang, H. & Huang, Y. A retrospective cohort study on pretreated neutrophil-to-lymphocyte ratio and prognosis of small cell lung cancer: Evidence of effect modification by chemotherapy regimen. Cancer Manag. Res. 12, 10341\u201310352. https:\/\/doi.org\/10.2147\/cmar.S263863 (2020).","journal-title":"Cancer Manag. Res."},{"key":"61145_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani, H., Matosevic, S., Khalid, A. B., Durm, G. & Jalal, S. I. Immunotherapy in lung cancer: Current landscape and future directions. Front. Immunol. 13, 823618. https:\/\/doi.org\/10.3389\/fimmu.2022.823618 (2022).","journal-title":"Front. Immunol."},{"key":"61145_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092522","author":"G Esposito","year":"2020","unstructured":"Esposito, G. et al. Immunotherapy in small cell lung cancer. Cancers https:\/\/doi.org\/10.3390\/cancers12092522 (2020).","journal-title":"Cancers"},{"key":"61145_CR38","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.3390\/curroncol28050347","volume":"28","author":"R El Sayed","year":"2021","unstructured":"El Sayed, R. & Blais, N. Immunotherapy in extensive-stage small cell lung cancer. Curr. Oncol. 28, 4093\u20134108. https:\/\/doi.org\/10.3390\/curroncol28050347 (2021).","journal-title":"Curr. Oncol."},{"key":"61145_CR39","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh, J. W. et al. Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J. Thorac. Oncol. 15, 1919\u20131927. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.022 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"61145_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu, S. V. et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619\u2013630. https:\/\/doi.org\/10.1200\/jco.20.01055 (2021).","journal-title":"J. Clin. Oncol."},{"key":"61145_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22964","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J. Clin. Lab. Anal. 33, e22964. https:\/\/doi.org\/10.1002\/jcla.22964 (2019).","journal-title":"J. Clin. Lab. Anal."},{"key":"61145_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.21037\/tlcr-20-541","volume":"10","author":"D Ksienski","year":"2021","unstructured":"Ksienski, D. et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Transl. Lung Cancer Res. 10, 355\u2013367. https:\/\/doi.org\/10.21037\/tlcr-20-541 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"61145_CR43","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.21873\/anticanres.13902","volume":"39","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa, T. et al. Association of high neutrophil-to-lymphocyte ratio with poor outcomes of pembrolizumab therapy in high-PD-L1-expressing non-small cell lung cancer. Anticancer Res. 39, 6851\u20136857. https:\/\/doi.org\/10.21873\/anticanres.13902 (2019).","journal-title":"Anticancer Res."},{"key":"61145_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cam4.1234","volume":"7","author":"T Shiroyama","year":"2018","unstructured":"Shiroyama, T. et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 7, 13\u201320. https:\/\/doi.org\/10.1002\/cam4.1234 (2018).","journal-title":"Cancer Med."},{"key":"61145_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100254","volume":"6","author":"G Mountzios","year":"2021","unstructured":"Mountzios, G. et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 6, 100254. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100254 (2021).","journal-title":"ESMO Open"},{"key":"61145_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4103\/jcrt.jcrt_1937_21","volume":"18","author":"H Yilmaz","year":"2022","unstructured":"Yilmaz, H. & Yersal, \u00d6. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J. Cancer Res. Ther. 18, 691\u2013696. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1937_21 (2022).","journal-title":"J. Cancer Res. Ther."},{"key":"61145_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/s0360-3016(02)04493-0","volume":"56","author":"KL Miller","year":"2003","unstructured":"Miller, K. L. et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 56, 355\u2013359. https:\/\/doi.org\/10.1016\/s0360-3016(02)04493-0 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"61145_CR48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/s0360-3016(03)00715-6","volume":"57","author":"KS Roof","year":"2003","unstructured":"Roof, K. S., Fidias, P., Lynch, T. J., Ancukiewicz, M. & Choi, N. C. Radiation dose escalation in limited-stage small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 57, 701\u2013708. https:\/\/doi.org\/10.1016\/s0360-3016(03)00715-6 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61145-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:16:35Z","timestamp":1714990595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61145-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61145"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61145-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10347"}}